No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Hosted on MSN1d
CRISPR-Cas9 Off-Target Effects: Challenges and SolutionsThe CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...
Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback